To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in groups 1, 2, and 3, as well as other rapidly emerging viruses that utilize…
Ended Awarded Last action
- Contract number
- 75N93020F00001
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $481,040
Award facts
- Contract value 82% obligated
-
- $481,040.00 Current, with exercised options
- $586,919.16 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35294, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $481,040 |
About this award
This delivery order was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to the University of Alabama at Birmingham to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in Groups 1, 2, and 3, as well as other rapidly emerging viruses that utilize the same assay methodology. The $586,919.16 contract was issued under the In Vitro Assessments of Antimicrobial Activity master IDIQ and will be performed in Birmingham, Alabama from September 2020 through September 2021 under a firm fixed price arrangement. The National Institute of Allergy and Infectious Diseases supports research on infectious, immunologic, and allergic diseases to better understand, treat, and ultimately prevent these conditions.
Description
To determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in groups 1, 2, and 3, as well as other rapidly emerging viruses that utilize the same assay methodology.
Quick answers
Who was awarded contract 75N93020F00001?
75N93020F00001 was awarded to University Of Alabama At Birmingham by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 17, 2020.
How much is contract 75N93020F00001 worth?
The government has obligated $481,040 on 75N93020F00001. Its potential value, with all options, is $586,919.
Is contract 75N93020F00001 an order under another contract?
Yes. 75N93020F00001 is a delivery order under 75N93019D00016, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93020F00001 competed?
The extent of competition for 75N93020F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award